PTCH1 and nevoid basal cell carcinoma syndrome: In general, the response to SMOi apparently depends on the mutational rate of the tumor: Nevoid basal cell carcinoma syndrome (NBCCS) patients with PTCH1 mutation but otherwise low mutational rate showed a 100% response rate without frequent and rapid drug resistance development during the study [86].